Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with its investment in Hemfrid
Mandate

Vinge has advised Fidelio Capital in connection with its investment in Hemfrid

August 27, 2021 M&A IT, Telecommunications and Outsourcing Corporate Commercial Employment and Benefits Real Estate and Construction Intellectual Property

Vinge has advised Fidelio Capital AB in its majority investment in Hemfrid i Sverige AB, the leading player within the home service industry in Sweden, with a revenue exceeding MSEK 700 and more than 2,000 employees in 2020. The transaction is subject to customary regulatory approvals and is expected to be completed during the second half of 2021.

Vinge’s team consisted of, among others, Daniel Rosvall, Jonas Bergström, Joacim Rydergård, Filip Öhrner, Christa Anttila, Hannah Kajlinger, Annie Fällström and Amanda Steen (M&A), Karolina Fuhrman and Mika Jordan (Corporate Commercial and IT), Felizia Wiker (IPR), Gustav Lindgren and Carl Östlund (Employment), Karolina Cohrs (Real Estate), and Sara Dahlros Sköld (VDR Assistant).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026